Feruloyl tyramine

Name: Feruloyl tyramine
Brand: MedChemExpress
SKU: HY-N11021
Rating: 4.5 (0 reviews)

Cat. No.: HY-N11021: Data Sheet Handling Instructions
FAQs
Technical Support

Feruloyl tyramine, an amide compound, can be isolated from ethanol extract of hemp seed. Feruloyl tyramine injected into the lateral ventricle caused hypothermia and dyskinesia in mice.

For research use only. We do not sell to patients.

Feruloyl tyramine Chemical Structure

CAS No. : 65646-26-6

Size	Stock	Quantity
5 mg	Get quote 2 - 3 weeks 1 - 2 Weeks 3 - 4 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
10 mg	Get quote 2 - 3 weeks 1 - 2 Weeks 3 - 4 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
25 mg	Get quote 2 - 3 weeks 1 - 2 Weeks 3 - 4 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
50 mg	Get quote 2 - 3 weeks 1 - 2 Weeks 3 - 4 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
100 mg	Get quote 2 - 3 weeks 1 - 2 Weeks 3 - 4 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

Synthetic products have potential research and development risk.

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 Customer Validation

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Feruloyl tyramine, an amide compound, can be isolated from ethanol extract of hemp seed. Feruloyl tyramine injected into the lateral ventricle caused hypothermia and dyskinesia in mice^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 30 3 Compound: 7	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 22951040]
A549	ED₅₀	13.35 6 Compound: 6	Cytotoxicity against human A549 cells after 7 days Cytotoxicity against human A549 cells after 7 days	[PMID: 1593281]
A549	ED₅₀	13.35 6 Compound: 6	Cytotoxicity against human A549 cells after 7 days Cytotoxicity against human A549 cells after 7 days	[PMID: 1593281]
A549	IC₅₀	> 30 3 Compound: 7	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 22951040]
A549	IC₅₀	> 40 3 Compound: 24	Antiproliferative activity against human A549 cells after 3 days by SRB assay Antiproliferative activity against human A549 cells after 3 days by SRB assay	[PMID: 25241925]
A549	IC₅₀	>40 3 Compound: 24	Antiproliferative activity against human A549 cells after 3 days by SRB assay Antiproliferative activity against human A549 cells after 3 days by SRB assay	[PMID: 25241925]
A549	IC₅₀	>30 3 Compound: 7	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 22951040]
A549	IC₅₀	> 40 3 Compound: 24	Antiproliferative activity against human A549 cells after 3 days by SRB assay Antiproliferative activity against human A549 cells after 3 days by SRB assay	[PMID: 25241925]
A549	ED₅₀	13.35 6 Compound: 6	Cytotoxicity against human A549 cells after 7 days Cytotoxicity against human A549 cells after 7 days	[PMID: 1593281]
BV-2	IC₅₀	17.36 3 Compound: 7	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production treated 30 mins before LPS stimulation measured after 24 hrs by Griess reaction Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production treated 30 mins before LPS stimulation measured after 24 hrs by Griess reaction	[PMID: 22951040]
BV-2	IC₅₀	17.36 3 Compound: 7	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production treated 30 mins before LPS stimulation measured after 24 hrs by Griess reaction Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production treated 30 mins before LPS stimulation measured after 24 hrs by Griess reaction	[PMID: 22951040]
BV-2	IC₅₀	17.36 3 Compound: 7	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production treated 30 mins before LPS stimulation measured after 24 hrs by Griess reaction Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production treated 30 mins before LPS stimulation measured after 24 hrs by Griess reaction	[PMID: 22951040]
BV-2	IC₅₀	18 3 Compound: 21	Antineuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 20 hrs by Griess assay Antineuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 20 hrs by Griess assay	[PMID: 33822610]
BV-2	IC₅₀	18 3 Compound: 21	Antineuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 20 hrs by Griess assay Antineuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 20 hrs by Griess assay	[PMID: 33822610]
DU-145	IC₅₀	>40 3 Compound: 24	Antiproliferative activity against human DU145 cells after 3 days by SRB assay Antiproliferative activity against human DU145 cells after 3 days by SRB assay	[PMID: 25241925]
BV-2	IC₅₀	18 3 Compound: 21	Antineuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 20 hrs by Griess assay Antineuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 20 hrs by Griess assay	[PMID: 33822610]
DU-145	IC₅₀	> 40 3 Compound: 24	Antiproliferative activity against human DU145 cells after 3 days by SRB assay Antiproliferative activity against human DU145 cells after 3 days by SRB assay	[PMID: 25241925]
Erythrocyte	IC₅₀	0.88 2 Compound: 25	Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway pretreated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometeric me Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway pretreated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometeric me	[PMID: 29631958]
Erythrocyte	IC₅₀	1.33 2 Compound: 25	Anticomplement activity in rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway pretreated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 mins by spectrophotomet Anticomplement activity in rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway pretreated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 mins by spectrophotomet	[PMID: 29631958]
DU-145	IC₅₀	> 40 3 Compound: 24	Antiproliferative activity against human DU145 cells after 3 days by SRB assay Antiproliferative activity against human DU145 cells after 3 days by SRB assay	[PMID: 25241925]
Erythrocyte	IC₅₀	1.33 2 Compound: 25	Anticomplement activity in rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway pretreated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 mins by spectrophotomet Anticomplement activity in rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway pretreated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 mins by spectrophotomet	[PMID: 29631958]
Erythrocyte	IC₅₀	0.88 2 Compound: 25	Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway pretreated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometeric me Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway pretreated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometeric me	[PMID: 29631958]
Erythrocyte	IC₅₀	0.88 2 Compound: 25	Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway pretreated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometeric me Anticomplement activity in sheep erythrocytes assessed as concentration required for 50% hemolytic inhibition by classic pathway pretreated for 10 mins with guinea pig serum followed by erythrocyte addition measured after 30 mins by spectrophotometeric me	[PMID: 29631958]
GES1	IC₅₀	> 150 3 Compound: 14	Antiproliferative activity against human GES1 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human GES1 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 35286954]
GES1	IC₅₀	>150 3 Compound: 14	Antiproliferative activity against human GES1 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human GES1 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 35286954]
Erythrocyte	IC₅₀	1.33 2 Compound: 25	Anticomplement activity in rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway pretreated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 mins by spectrophotomet Anticomplement activity in rabbit erythrocytes assessed as concentration required for 50% hemolytic inhibition by alternative pathway pretreated for 10 mins with normal human serum followed by erythrocyte addition measured after 30 mins by spectrophotomet	[PMID: 29631958]
GES1	IC₅₀	> 150 3 Compound: 14	Antiproliferative activity against human GES1 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human GES1 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 35286954]
HCT-15	IC₅₀	> 30 3 Compound: 7	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 22951040]
HCT-15	IC₅₀	>30 3 Compound: 7	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 22951040]
HCT-15	IC₅₀	> 30 3 Compound: 7	Cytotoxicity against human HCT15 cells by SRB assay Cytotoxicity against human HCT15 cells by SRB assay	[PMID: 22951040]
HepG2	IC₅₀	6.6 6 Compound: 6	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 11374955]
HepG2	IC₅₀	6.6 6 Compound: 6	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 11374955]
HGC-27	IC₅₀	84.5 3 Compound: 14	Antiproliferative activity against human HGC-27 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human HGC-27 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 35286954]
HepG2 2.2.15	IC₅₀	1.9 6 Compound: 6	Cytotoxicity against human HepG2(2.2.15) cells by MTT assay Cytotoxicity against human HepG2(2.2.15) cells by MTT assay	[PMID: 11374955]
HepG2 2.2.15	IC₅₀	1.9 6 Compound: 6	Cytotoxicity against human HepG2(2.2.15) cells by MTT assay Cytotoxicity against human HepG2(2.2.15) cells by MTT assay	[PMID: 11374955]
HGC-27	IC₅₀	84.5 3 Compound: 14	Antiproliferative activity against human HGC-27 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human HGC-27 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 35286954]
HT-29	ED₅₀	23.58 6 Compound: 6	Cytotoxicity against human HT-29 cells after 7 days Cytotoxicity against human HT-29 cells after 7 days	[PMID: 1593281]
HGC-27	IC₅₀	84.5 3 Compound: 14	Antiproliferative activity against human HGC-27 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human HGC-27 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 35286954]
HT-29	ED₅₀	23.58 6 Compound: 6	Cytotoxicity against human HT-29 cells after 7 days Cytotoxicity against human HT-29 cells after 7 days	[PMID: 1593281]
HT-29	IC₅₀	> 20 3 Compound: 17	Cytotoxicity against human HT-29 cells assessed as reduction in cell growth incubated for 72 hrs Cytotoxicity against human HT-29 cells assessed as reduction in cell growth incubated for 72 hrs	[PMID: 26147490]
HT-29	IC₅₀	> 20 3 Compound: 17	Cytotoxicity against human HT-29 cells assessed as reduction in cell growth incubated for 72 hrs Cytotoxicity against human HT-29 cells assessed as reduction in cell growth incubated for 72 hrs	[PMID: 26147490]
HT-29	ED₅₀	23.58 6 Compound: 6	Cytotoxicity against human HT-29 cells after 7 days Cytotoxicity against human HT-29 cells after 7 days	[PMID: 1593281]
HT-29	IC₅₀	>20 3 Compound: 17	Cytotoxicity against human HT-29 cells assessed as reduction in cell growth incubated for 72 hrs Cytotoxicity against human HT-29 cells assessed as reduction in cell growth incubated for 72 hrs	[PMID: 26147490]
HepG2	IC₅₀	6.6 6 Compound: 6	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 11374955]
KB	IC₅₀	>40 3 Compound: 24	Antiproliferative activity against human KB cells after 3 days by SRB assay Antiproliferative activity against human KB cells after 3 days by SRB assay	[PMID: 25241925]
KB	IC₅₀	> 40 3 Compound: 24	Antiproliferative activity against human KB cells after 3 days by SRB assay Antiproliferative activity against human KB cells after 3 days by SRB assay	[PMID: 25241925]
HepG2 2.2.15	IC₅₀	1.9 6 Compound: 6	Cytotoxicity against human HepG2(2.2.15) cells by MTT assay Cytotoxicity against human HepG2(2.2.15) cells by MTT assay	[PMID: 11374955]
KB	IC₅₀	> 47.8 3 Compound: 12	Cytotoxicity against human KB cells by sulforhodamine B assay Cytotoxicity against human KB cells by sulforhodamine B assay	[PMID: 26928423]
KB	IC₅₀	>47.8 3 Compound: 12	Cytotoxicity against human KB cells by sulforhodamine B assay Cytotoxicity against human KB cells by sulforhodamine B assay	[PMID: 26928423]
LNCaP	IC₅₀	>100 3 Compound: 5	Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay	[PMID: 11858758]
LNCaP	IC₅₀	> 100 3 Compound: 5	Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay	[PMID: 11858758]
KB	IC₅₀	> 40 3 Compound: 24	Antiproliferative activity against human KB cells after 3 days by SRB assay Antiproliferative activity against human KB cells after 3 days by SRB assay	[PMID: 25241925]
KB	IC₅₀	> 47.8 3 Compound: 12	Cytotoxicity against human KB cells by sulforhodamine B assay Cytotoxicity against human KB cells by sulforhodamine B assay	[PMID: 26928423]
MCF7	ED₅₀	4.76 6 Compound: 6	Cytotoxicity against human MCF7 cells after 7 days Cytotoxicity against human MCF7 cells after 7 days	[PMID: 1593281]
MCF7	IC₅₀	> 40 3 Compound: 24	Antiproliferative activity against human MCF7 cells after 3 days by SRB assay Antiproliferative activity against human MCF7 cells after 3 days by SRB assay	[PMID: 25241925]
LNCaP	IC₅₀	> 100 3 Compound: 5	Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay	[PMID: 11858758]
MCF7	ED₅₀	4.76 6 Compound: 6	Cytotoxicity against human MCF7 cells after 7 days Cytotoxicity against human MCF7 cells after 7 days	[PMID: 1593281]
MCF7	IC₅₀	>40 3 Compound: 24	Antiproliferative activity against human MCF7 cells after 3 days by SRB assay Antiproliferative activity against human MCF7 cells after 3 days by SRB assay	[PMID: 25241925]
MDA-MB-231	IC₅₀	> 40 3 Compound: 24	Antiproliferative activity against human MDA-MB-231 cells after 3 days by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 3 days by SRB assay	[PMID: 25241925]
MDA-MB-231	IC₅₀	>40 3 Compound: 24	Antiproliferative activity against human MDA-MB-231 cells after 3 days by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 3 days by SRB assay	[PMID: 25241925]
MCF7	ED₅₀	4.76 6 Compound: 6	Cytotoxicity against human MCF7 cells after 7 days Cytotoxicity against human MCF7 cells after 7 days	[PMID: 1593281]
MDA-MB-435	IC₅₀	> 20 3 Compound: 17	Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell growth incubated for 72 hrs Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell growth incubated for 72 hrs	[PMID: 26147490]
MCF7	IC₅₀	> 40 3 Compound: 24	Antiproliferative activity against human MCF7 cells after 3 days by SRB assay Antiproliferative activity against human MCF7 cells after 3 days by SRB assay	[PMID: 25241925]
MDA-MB-435	IC₅₀	>20 3 Compound: 17	Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell growth incubated for 72 hrs Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell growth incubated for 72 hrs	[PMID: 26147490]
MDA-MB-231	IC₅₀	> 40 3 Compound: 24	Antiproliferative activity against human MDA-MB-231 cells after 3 days by SRB assay Antiproliferative activity against human MDA-MB-231 cells after 3 days by SRB assay	[PMID: 25241925]
MGC-803	IC₅₀	98.3 3 Compound: 14	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 35286954]
MGC-803	IC₅₀	98.3 3 Compound: 14	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 35286954]
MDA-MB-435	IC₅₀	> 20 3 Compound: 17	Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell growth incubated for 72 hrs Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell growth incubated for 72 hrs	[PMID: 26147490]
RAW264.7	IC₅₀	> 50 3 Compound: 25	Antiinflammatory activity in mouse RAW264.7 assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess reagent based assay Antiinflammatory activity in mouse RAW264.7 assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess reagent based assay	[PMID: 33939429]
RAW264.7	IC₅₀	6.33 3 Compound: 9	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production preincubated for 1 hr followed by LPS-stimulation and measured after 18 hrs Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production preincubated for 1 hr followed by LPS-stimulation and measured after 18 hrs	[PMID: 31126853]
MGC-803	IC₅₀	98.3 3 Compound: 14	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability after 24 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 35286954]
RAW264.7	IC₅₀	6.33 3 Compound: 9	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production preincubated for 1 hr followed by LPS-stimulation and measured after 18 hrs Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production preincubated for 1 hr followed by LPS-stimulation and measured after 18 hrs	[PMID: 31126853]
RAW264.7	IC₅₀	>50 3 Compound: 25	Antiinflammatory activity in mouse RAW264.7 assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess reagent based assay Antiinflammatory activity in mouse RAW264.7 assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess reagent based assay	[PMID: 33939429]
RAW264.7	IC₅₀	6.33 3 Compound: 9	Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production preincubated for 1 hr followed by LPS-stimulation and measured after 18 hrs Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced PGE2 production preincubated for 1 hr followed by LPS-stimulation and measured after 18 hrs	[PMID: 31126853]
SK-BR-3	IC₅₀	> 40 3 Compound: 24	Antiproliferative activity against human SK-BR-3 cells after 3 days by SRB assay Antiproliferative activity against human SK-BR-3 cells after 3 days by SRB assay	[PMID: 25241925]
SK-BR-3	IC₅₀	>40 3 Compound: 24	Antiproliferative activity against human SK-BR-3 cells after 3 days by SRB assay Antiproliferative activity against human SK-BR-3 cells after 3 days by SRB assay	[PMID: 25241925]
RAW264.7	IC₅₀	> 50 3 Compound: 25	Antiinflammatory activity in mouse RAW264.7 assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess reagent based assay Antiinflammatory activity in mouse RAW264.7 assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess reagent based assay	[PMID: 33939429]
SK-MEL-2	IC₅₀	>30 3 Compound: 7	Cytotoxicity against human SK-MEL-2 cells by SRB assay Cytotoxicity against human SK-MEL-2 cells by SRB assay	[PMID: 22951040]
SK-MEL-2	IC₅₀	> 30 3 Compound: 7	Cytotoxicity against human SK-MEL-2 cells by SRB assay Cytotoxicity against human SK-MEL-2 cells by SRB assay	[PMID: 22951040]
SK-OV-3	IC₅₀	> 30 3 Compound: 7	Cytotoxicity against human SKOV3 cells by SRB assay Cytotoxicity against human SKOV3 cells by SRB assay	[PMID: 22951040]
SK-OV-3	IC₅₀	>30 3 Compound: 7	Cytotoxicity against human SKOV3 cells by SRB assay Cytotoxicity against human SKOV3 cells by SRB assay	[PMID: 22951040]
SK-BR-3	IC₅₀	> 40 3 Compound: 24	Antiproliferative activity against human SK-BR-3 cells after 3 days by SRB assay Antiproliferative activity against human SK-BR-3 cells after 3 days by SRB assay	[PMID: 25241925]
Vero	IC₅₀	>47.8 3 Compound: 12	Cytotoxicity against African green monkey Vero cells by sulforhodamine B assay Cytotoxicity against African green monkey Vero cells by sulforhodamine B assay	[PMID: 26928423]
Vero	IC₅₀	> 47.8 3 Compound: 12	Cytotoxicity against African green monkey Vero cells by sulforhodamine B assay Cytotoxicity against African green monkey Vero cells by sulforhodamine B assay	[PMID: 26928423]
SK-MEL-2	IC₅₀	> 30 3 Compound: 7	Cytotoxicity against human SK-MEL-2 cells by SRB assay Cytotoxicity against human SK-MEL-2 cells by SRB assay	[PMID: 22951040]
ZR-75-1	IC₅₀	>40 3 Compound: 24	Antiproliferative activity against human ZR-75-1 cells after 3 days by SRB assay Antiproliferative activity against human ZR-75-1 cells after 3 days by SRB assay	[PMID: 25241925]
ZR-75-1	IC₅₀	> 40 3 Compound: 24	Antiproliferative activity against human ZR-75-1 cells after 3 days by SRB assay Antiproliferative activity against human ZR-75-1 cells after 3 days by SRB assay	[PMID: 25241925]
SK-OV-3	IC₅₀	> 30 3 Compound: 7	Cytotoxicity against human SKOV3 cells by SRB assay Cytotoxicity against human SKOV3 cells by SRB assay	[PMID: 22951040]
Vero	IC₅₀	> 47.8 3 Compound: 12	Cytotoxicity against African green monkey Vero cells by sulforhodamine B assay Cytotoxicity against African green monkey Vero cells by sulforhodamine B assay	[PMID: 26928423]
ZR-75-1	IC₅₀	> 40 3 Compound: 24	Antiproliferative activity against human ZR-75-1 cells after 3 days by SRB assay Antiproliferative activity against human ZR-75-1 cells after 3 days by SRB assay	[PMID: 25241925]

In Vivo

Feruloyl tyramine (133 μg/mouse, 200 μg/mouse; i.c.v.; single dose) caused hypothermia and dyskinesia in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

313.35

Formula

C₁₈H₁₉NO₄

CAS No.

65646-26-6

SMILES

O=C(NCCC1=CC=C(O)C=C1)/C=C/C2=CC=C(O)C(OC)=C2

Structure Classification

Alkaloids

Phenols

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Yamamoto I, et al. Analysis and pharmacotoxicity of feruloyltyramine as a new constituent and p-coumaroyltyramine in Cannabis sativa L. Pharmacol Biochem Behav. 1991 Nov;40(3):465-9. [Content Brief]